Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies-Reference-Cited by-同舟云学术

Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies

Published:2020-10 Issue: Volume:204 Page:112492
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Nunes Isabelle Karine da Costa,de Souza Everton Tenório,Martins Italo Rossi Roseno,Barbosa Gisele,Moraes Junior Manoel Oliveira de,Medeiros Millena de Melo,Silva Sheyla Welma Duarte,Balliano Tatiane Luciano,da Silva Bagnólia Araújo,Silva Patrícia Machado Rodrigues,Carvalho Vinicius de Frias,Martins Marco Aurélio,Lima Lidia Moreira

Funder

CNPq

FAPERJ

CAPES

INCT-INOFAR

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference49 articles.

1. Phosphodiesterase 4-targeted treatments for autoimmune diseases;Kumar;BMC Med.,2013

2. A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast;Chiricozzi;Expet Rev. Clin. Immunol.,2016